Amneal raises 2026 guidance on Q3 revenue growth, Kashiv integration progress

Amneal Pharmaceuticals reported results for the third quarter ended September 30, 2026 on November 3, 2026. Net revenue for the quarter reached $863 million, up 10% from $785 million a year earlier.¹ The Affordable Medicines segment grew 19% on biosimilars, women's health patches, and new launches, while Specialty revenue rose 20% on branded products including CREXONT, the BREKIYA autoinjector, and UNITHROID.¹ AvKARE revenue fell 17%, which the company attributed to a non-recurring cardiovascular product launch in the prior-year period.¹

On profitability, the company posted a net loss attributable to Amneal of $22 million, compared with net income of $2 million in the third quarter of 2025, as higher revenue and gross profit were offset by non-recurring acquisition and integration costs and a higher tax provision.¹ Adjusted EBITDA came in at $207 million, a 30% increase year over year.¹

Looking ahead, executives pointed to a pipeline of upcoming launches. Chirag and Chintu Patel, the company's co-founders and co-CEOs, said performance heading into 2027 is being driven by catalysts including Women's Health patches, biosimilars, injectables such as lanreotide, CREXONT, and the BREKIYA autoinjector.¹ They also said the integration of Kashiv is proceeding well, with long-term growth potential in biosimilars.¹

The company raised its full-year outlook. Updated 2026 guidance calls for net revenue of $3.15 billion to $3.25 billion, up from a prior range of $3.10 billion to $3.20 billion; adjusted EBITDA of $800 million to $815 million, up from $750 million to $780 million; and adjusted diluted EPS of $1.04 to $1.08, up from $0.96 to $1.06.¹ The company also updated its operating cash flow guidance to reflect working capital needs, including higher inventory levels in key growth areas.¹